Trial Profile
Single- and multiple-ascending dose study of ABT 288 in younger volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jan 2013
Price :
$35
*
At a glance
- Drugs ABT 288 (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories
- 08 Jan 2013 New trial record